Urogen Pharma Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Theracoat Ltd. (to 2015)
2
Ending by 2030
Feb 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 26, 2026The maintenance fee for Material and Method for Treating Internal Cavities (US 9,040,074) comes due Nov 26, 2026. Unpaid by May 26, 2027, it lapses early.
- 1 fee due Dec 30, 2026The maintenance fee for Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration (US 9,066,940) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Feb 18, 2027The maintenance fee for Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration (US 9,107,919) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 3 fees due May 3 to 12, 2027 · next May 3
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,107,919 | Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration In force · High confidence | In force | High confidence | |
| US 9,066,940 | Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration In force · High confidence | In force | High confidence | |
| US 9,040,074 | Material and Method for Treating Internal Cavities In force · High confidence | In force | High confidence | |
| US 9,950,069 | Material and Method for Treating Internal Cavities In force · High confidence | In force | High confidence | |
| US 10,039,832 | Material and Method for Treating Internal Cavities In force · High confidence | In force | High confidence | |
| US 10,471,150 | Material and Method for Treating Internal Cavities In force · High confidence | In force | High confidence | |
| US 9,173,936 | Phospholipid Drug Analogs In force · Medium confidence | In force | Medium confidence | |
| US 9,180,183 | Phospholipid Drug Analogs In force · Medium confidence | In force | Medium confidence | |
| US 9,540,407 | Phospholipid Drug Analogs In force · Medium confidence | In force | Medium confidence | |
| US 9,801,854 | Slow Release Formulations of Cell Cycle Regulators and Anti-Cancer Agents for Local Treatment of Solid Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 17: 2 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 13 abandoned